METHOD FOR DETERMINING PROGRESSION OF JOINT DESTRUCTION IN A PATIENT SUFFERING RHEUMATOID ARTHRITIS BACKGROUND OF 5-YEAR THERAPY OF BASIC ANTI-INFLAMMATORY DRUGS OR BASIC ANTI-INFLAMMATORY DRUGS IN COMBINATION WITH GENETICALLY ENGINEERED BIOLOGICAL PREPARATIONS AND / OR PSYCHOPHARMACOTHERAPY AND ACCOMPANYING ANXIETY-DEPRESSIVE DISORDER Russian patent published in 2020 - IPC A61B5/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to rheumatology. Patient suffering rheumatoid arthritis is examined for duration of rheumatoid arthritis in years. Value of the maximal manifestation of pain on the BPI (BPImax) scale before the beginning of the therapy, in points, is determined. Duration of comorbid anxiety-depressive disorder in years is determined. Clinically significant fatigue is determined (FSS≥4) according to FSS scale before therapy. Presence of extra-articular manifestations of rheumatoid arthritis is determined before therapy. Presence of a recurrent depressive disorder is determined after 5-year therapy of rheumatoid arthritis. 5-year therapeutic regimen is determined. Based on the set of obtained data, progressing of joint destruction (Y) is determined by original formula. If Y is more than 0.746, the progression of joint destruction is stated against background of 5-year therapy.

EFFECT: method enables detecting progression of joint destruction in patients with rheumatoid arthritis and associated anxiety-depressive disorder background of 5-year therapy.

1 cl, 5 tbl, 2 ex